Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1/2 13Phase 3 10Phase 1 7Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 7Cyclophosphamide 5Metformin 4durvalumab 3Vincristine 3Radiation 3Imiquimod 3Fluorouracil 3antitumor A 2Testosterone 2Surveys and Questionnaires 2Rituximab 2Prednisone 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Lapatinib 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Cisplatin 2Biopsy 2xentuzumab 1tremelimumab 1ribociclib 1posaconazole 1pexidartinib 1perflutren 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Has results × tremelimumab × Clear all
NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
16 enrolled 8 charts
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡